Invention Grant
- Patent Title: 2-cyanoisoindoline derivatives for treating cancer
-
Application No.: US16080506Application Date: 2017-03-17
-
Publication No.: US10683269B2Publication Date: 2020-06-16
- Inventor: Karl Richard Gibson , Alison Jones , Mark Ian Kemp , Andrew Madin , Martin Lee Stockley , Gavin Alistair Whitlock , Michael D Woodrow , Keith Allan Menear
- Applicant: MISSION THERAPEUTICS LIMITED
- Applicant Address: GB Cambridge
- Assignee: MISSION THERAPEUTICS LIMITED
- Current Assignee: MISSION THERAPEUTICS LIMITED
- Current Assignee Address: GB Cambridge
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@53ca7346
- International Application: PCT/GB2017/050763 WO 20170317
- International Announcement: WO2017/158388 WO 20170921
- Main IPC: C07D209/44
- IPC: C07D209/44 ; C07D403/10 ; C07D403/04 ; C07D401/04 ; C07D471/04 ; C07D413/04 ; C07D401/12 ; C07D413/12 ; C07D409/12 ; A61P35/00 ; C07D519/00 ; C07D403/14 ; C07D487/04 ; C07D401/06 ; C07D405/12 ; C07D401/14 ; C07D413/14 ; C07D413/10 ; C07D403/12 ; C07D417/12
Abstract:
The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.
Public/Granted literature
- US20190010122A1 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER Public/Granted day:2019-01-10
Information query
